Hereditary Angioedema Market Size was ~USD 2,400 Million in 2023 to Witness Growth by 2032, Estimates DelveInsight
Hereditary Angioedema Market
DelveInsight’s Hereditary Angioedema Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.
LAS VEGAS, NEVADA, UNITED STATES, April 3, 2024 /EINPresswire.com/ --
The Hereditary Angioedema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.
DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast
Some of the key facts of the Hereditary Angioedema Market Report:
The Hereditary Angioedema market size was valued approximately USD 2,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
Throughout all the Seven Major Markets (7MM), the United States consistently maintained the largest market size, estimated to be nearly USD 2,000 million in 2023. This figure is projected to increase during the forecast period from 2024 to 2034.
In Feb 2024, BioCryst introduced ORLADEYO (berotralstat) in Italy.
In Jan 2024, Ionis disclosed favorable topline findings from the Phase III OASIS-HAE study evaluating the investigational drug donidalorsen in individuals with hereditary angioedema. Based on these results, Ionis is in the process of preparing a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA).
In Dec 2023, CSL Behring has declared that the FDA has acknowledged a Biologics License Application (BLA) for garadacimab (CSL312) as a monthly prophylactic treatment for hereditary angioedema (HAE).
In 2023, the total number of diagnosed prevalent cases of hereditary angioedema (HAE) across the Seven Major Markets (7MM) was 13,900. It is anticipated that this figure will experience a significant compound annual growth rate (CAGR) by the year 2034.
Within the EU4 and the UK region, the United Kingdom exhibited the largest diagnosed prevalent population of hereditary angioedema (HAE), with almost 1,400 cases, followed closely by Germany, which reported 1,300 diagnosed prevalent cases in 2023. Conversely, Spain and Italy had the lowest diagnosed prevalent populations, each with fewer than 1,000 cases in 2023.
The developing pipeline for Hereditary Angioedema (HAE) includes numerous drugs designed for both prophylactic and treatment purposes. Examples include garadacimab, donidalorsen, KVD900, NTLA2002, and various others, each targeting a wide array of mechanisms.
Potential therapeutic targets include blocking the bradykinin-B2-receptor, plasma kallikrein inhibitor, inhibiting factor XII (for example, by using a blocking antibody), and preventing the cleavage of prekallikrein. In addition, a small number of gene treatments are being developed to treat Hereditary Angioedema; they will aid in the treatment of recently discovered mutations such FXII and PLG HAE.
Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
The Hereditary Angioedema epidemiology based on gender analyzed that the diagnosed prevalent cases of Hereditary Angioedema in the 7MM varied according to gender, with prevalent cases higher in females than males
The Hereditary Angioedema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.
Hereditary Angioedema Overview
Rarely occurring hereditary angioedema (HAE) is characterized by recurrent episodes of localized subcutaneous (SC) or mucosal edema, most commonly affecting the oropharynx, upper respiratory tract, skin, and intestines.
Get a Free sample for the Hereditary Angioedema Market Report:
https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr
Hereditary Angioedema Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hereditary Angioedema Epidemiology Segmentation:
The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Hereditary Angioedema
Prevalent Cases of Hereditary Angioedema by severity
Gender-specific Prevalence of Hereditary Angioedema
Diagnosed Cases of Episodic and Chronic Hereditary Angioedema
Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast
Hereditary Angioedema Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hereditary Angioedema Therapies and Key Companies
KVD900: KalVista Pharmaceuticals
NTLA-2002: Intellia Therapeutics
BMN 331: BioMarin Pharmaceutical
Garadacimab: CSL Behring
Donidalorse: Ionis Pharmaceuticals
STAR-0215: Astria Therapeutics
PHA121: Pharvaris Netherlands B.V
NTLA-2002: Intellia Therapeutics
TAK-743: Takeda
KVD900: KalVista Pharmaceuticals
CSL312: CSL Behring
Lanadelumab: Shire
Hereditary Angioedema Market Strengths
Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes
Hereditary Angioedema Market Opportunities
Proliferating demand for therapies with improved patient compliance, fewer side effects, improved resistance profile, and long-acting therapies
Scope of the Hereditary Angioedema Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and Hereditary Angioedema emerging therapies
Hereditary Angioedema Market Dynamics: Hereditary Angioedema market drivers and Hereditary Angioedema market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hereditary Angioedema Unmet Needs, KOL’s views, Analyst’s views, Hereditary Angioedema Market Access and Reimbursement
To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hereditary Angioedema Market Report Introduction
2. Executive Summary for Hereditary Angioedema
3. SWOT analysis of Hereditary Angioedema
4. Hereditary Angioedema Patient Share (%) Overview at a Glance
5. Hereditary Angioedema Market Overview at a Glance
6. Hereditary Angioedema Disease Background and Overview
7. Hereditary Angioedema Epidemiology and Patient Population
8. Country-Specific Patient Population of Hereditary Angioedema
9. Hereditary Angioedema Current Treatment and Medical Practices
10. Hereditary Angioedema Unmet Needs
11. Hereditary Angioedema Emerging Therapies
12. Hereditary Angioedema Market Outlook
13. Country-Wise Hereditary Angioedema Market Analysis (2019–2032)
14. Hereditary Angioedema Market Access and Reimbursement of Therapies
15. Hereditary Angioedema Market Drivers
16. Hereditary Angioedema Market Barriers
17. Hereditary Angioedema Appendix
18. Hereditary Angioedema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
